DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 148 filers reported holding DENALI THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $370,515 | -30.1% | 17,960 | +0.1% | 0.00% | -25.0% |
| Q2 2023 | $529,705 | +129412.2% | 17,950 | +1.1% | 0.00% | +33.3% |
| Q1 2023 | $409 | -17.9% | 17,758 | -0.9% | 0.00% | -25.0% |
| Q4 2022 | $498 | -99.9% | 17,918 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $544,000 | +3.8% | 17,918 | +0.6% | 0.01% | 0.0% |
| Q2 2022 | $524,000 | +523.8% | 17,816 | +581.0% | 0.01% | +400.0% |
| Q1 2022 | $84,000 | -36.4% | 2,616 | -32.1% | 0.00% | 0.0% |
| Q4 2021 | $132,000 | -57.4% | 3,851 | -37.3% | 0.00% | -50.0% |
| Q3 2021 | $310,000 | -36.2% | 6,146 | -0.8% | 0.00% | -33.3% |
| Q2 2021 | $486,000 | +35.4% | 6,194 | -1.6% | 0.00% | +50.0% |
| Q1 2021 | $359,000 | -26.6% | 6,294 | +7.7% | 0.00% | -33.3% |
| Q4 2020 | $489,000 | +425.8% | 5,844 | +125.6% | 0.00% | +200.0% |
| Q3 2020 | $93,000 | +416.7% | 2,590 | +240.8% | 0.00% | – |
| Q2 2020 | $18,000 | +125.0% | 760 | +65.2% | 0.00% | – |
| Q1 2020 | $8,000 | – | 460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |